Overall, these in vivo and clinical experiments provide compelling evidence supporting the role of the NSUN5/WDR5‐SMAD3‐EMT axis in promoting the malignant progression of HCC, underscoring its significant clinical implications. The gene discussed is SMAD3; the disease is hepatocellular carcinoma.